Literature DB >> 23015364

Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership.

Patrick B Ryan1, David Madigan, Paul E Stang, J Marc Overhage, Judith A Racoosin, Abraham G Hartzema.   

Abstract

BACKGROUND: Expanded availability of observational healthcare data (both administrative claims and electronic health records) has prompted the development of statistical methods for identifying adverse events associated with medical products, but the operating characteristics of these methods when applied to the real-world data are unknown.
METHODS: We studied the performance of eight analytic methods for estimating of the strength of association-relative risk (RR) and associated standard error of 53 drug-adverse event outcome pairs, both positive and negative controls. The methods were applied to a network of ten observational healthcare databases, comprising over 130 million lives. Performance measures included sensitivity, specificity, and positive predictive value of methods at RR thresholds achieving statistical significance of p < 0.05 or p < 0.001 and with absolute threshold RR > 1.5, as well as threshold-free measures such as area under receiver operating characteristic curve (AUC).
RESULTS: Although no specific method demonstrated superior performance, the aggregate results provide a benchmark and baseline expectation for risk identification method performance. At traditional levels of statistical significance (RR > 1, p < 0.05), all methods have a false positive rate >18%, with positive predictive value <38%. The best predictive model, high-dimensional propensity score, achieved an AUC  =  0.77. At 50% sensitivity, false positive rate ranged from 16% to 30%. At 10% false positive rate, sensitivity of the methods ranged from 9% to 33%.
CONCLUSIONS: Systematic processes for risk identification can provide useful information to supplement an overall safety assessment, but assessment of methods performance suggests a substantial chance of identifying false positive associations.
Copyright © 2012 John Wiley & Sons, Ltd.

Mesh:

Year:  2012        PMID: 23015364     DOI: 10.1002/sim.5620

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  76 in total

1.  A method for systematic discovery of adverse drug events from clinical notes.

Authors:  Guan Wang; Kenneth Jung; Rainer Winnenburg; Nigam H Shah
Journal:  J Am Med Inform Assoc       Date:  2015-07-31       Impact factor: 4.497

2.  Evidence of Misclassification of Drug-Event Associations Classified as Gold Standard 'Negative Controls' by the Observational Medical Outcomes Partnership (OMOP).

Authors:  Manfred Hauben; Jeffrey K Aronson; Robin E Ferner
Journal:  Drug Saf       Date:  2016-05       Impact factor: 5.606

3.  Assessment of vibration of effects due to model specification can demonstrate the instability of observational associations.

Authors:  Chirag J Patel; Belinda Burford; John P A Ioannidis
Journal:  J Clin Epidemiol       Date:  2015-06-06       Impact factor: 6.437

4.  How Confident Are We about Observational Findings in Healthcare: A Benchmark Study.

Authors:  Martijn J Schuemie; M Soledad Cepeda; Marc A Suchard; Jianxiao Yang; Yuxi Tian; Alejandro Schuler; Patrick B Ryan; David Madigan; George Hripcsak
Journal:  Harv Data Sci Rev       Date:  2020-01-31

5.  Ongoing challenges in pharmacovigilance.

Authors:  Gerald J Dal Pan
Journal:  Drug Saf       Date:  2014-01       Impact factor: 5.606

6.  Empirical performance of a new user cohort method: lessons for developing a risk identification and analysis system.

Authors:  Patrick B Ryan; Martijn J Schuemie; Susan Gruber; Ivan Zorych; David Madigan
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

7.  Replication of the OMOP experiment in Europe: evaluating methods for risk identification in electronic health record databases.

Authors:  Martijn J Schuemie; Rosa Gini; Preciosa M Coloma; Huub Straatman; Ron M C Herings; Lars Pedersen; Francesco Innocenti; Giampiero Mazzaglia; Gino Picelli; Johan van der Lei; Miriam C J M Sturkenboom
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

Review 8.  Desideratum for evidence based epidemiology.

Authors:  J Marc Overhage; Patrick B Ryan; Martijn J Schuemie; Paul E Stang
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

9.  Pharmacovigilance via Baseline Regularization with Large-Scale Longitudinal Observational Data.

Authors:  Zhaobin Kuang; Peggy Peissig; Vítor Santos Costa; Richard Maclin; David Page
Journal:  KDD       Date:  2017-08

10.  Signalling paediatric side effects using an ensemble of simple study designs.

Authors:  Jenna M Reps; Jonathan M Garibaldi; Uwe Aickelin; Daniele Soria; Jack E Gibson; Richard B Hubbard
Journal:  Drug Saf       Date:  2014-03       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.